Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 Report Overview:
- Controlled Release Drug Delivery Market Opportunity: > 90 Billion By 2028
- Global & Regional Market Forecast Till 2028
- Controlled Release Drug Clinical Pipeline Insight By Phase, Indication, Company, Country & Drug Class
- Comprehensive Clinical insight On More Than 200 Drug in Clinical Trials
- Comprehensive Clinical insight On More Than 150 Drug Available in market
- Drug Pricing, Patent & Dosage Insight By indication: Alzheimer’s, Parkinson’s, Schizophrenia , Chronic Pain, Multiple Sclerosis, Diabetes Mellitus, Hypertension & Angina Pectoris
Download Report: https://www.kuickresearch.com/report-controlled-release-drug-delivery-system-market
In the last few decades, controlled release drugs and formulations have been going up the ranks in terms of the attention they are receiving in the pharmaceutical industry. Controlled release drugs offer significant benefits over their other counterparts like avoiding overdosing, which is why many drugs are now being released in the form of controlled release and controlled release capsules. These drugs have been developed for a wide diversity of indications and now count for a substantial portion of the global pharmaceutical market. Their popularity is anticipated to increase over time due to the advantages they provide over conventional medications, which will also enable them to draw off market money from their original drugs.
Controlled release drugs are developed as two major categories which depend on whether they are encapsulated by a polymer matrix or a polymer coating. Both have their pros and cons but are ultimately used to make these drugs. In addition to capsules, these medications are also offered as transdermal patches, which have significantly improved patient compliance. When working with children or senior persons, these patches come in handy. Adlarity (donepezil transdermal system), created by Corium, received FDA approval in March 2022 as a treatment for those with mild, moderate, or severe Alzheimer disease. The patch was commercially released in the market at the end of September that same year. The only product on the market made specifically to deliver donepezil is the medication. The transdermal patch aids in preventing the unpleasant gastrointestinal reactions linked to the medication’s oral form.
The field of controlled drug release has also been impacted by nanotechnology, just like other medical and pharmaceutical fields. It is possible to design a nanomedicine so that biological enzymes cannot break it down. This can help with a controlled drug release, enabling the gradual release of a single targeted dose over time. Controlled, continuous release lessens the need for medication administration, boosts treatment adherence, and keeps the body’s level of the drug steady.
The development of these drugs has piqued the interest of numerous established and emerging businesses, for which funding has flowed in from numerous sources. On the strength of non- clinical ocular safety and efficiency tests, funders have strengthened Re-Vana Therapeutics’ goal to work on and develop controlled -release medications for eye diseases, contributing US$ 11.9 million in series A funding. Re-Vana, a company that was formed from Queen’s University in Northern Ireland, wants to create implants that slowly release medications, like biodegradable devices at the back of the eye. Additionally, the company also has a proprietary technology that it intends to deploy to achieve its goal.
Companies have also started forming alliances with other companies pursue their interests. Iveric Bio and DelSiTech announced an exclusive global licencing deal in July 2022 that would allow Iveric Bio to create and market new Zimura (avacincaptad pegol) formulations utilising DelSiTech’s silica-based sustained release technology. These technologies may be able to help individuals who are receiving treatment for intermediate AMD and geographic atrophy (GA). A new complement C5 protein inhibitor called Zimura is being developed to treat geographic atrophy (GA), which results from age-related macular degeneration (AMD). Zimura is anticipated to reach a larger patient base by introducing prolonged release formulations, which will be advantageous for both of the drug’s developers.
Drugs with controlled release offer a number of benefits that restrict the market’s usage of conventional medications. Compared to their competitors, oral controlled release tablets deliver the medication release in a different manner. It is a powerful method for ensuring maximal patient compliance while determining the therapeutic goals. The two main benefits of it, besides the many others, are its cost effectiveness and once-daily dosage. It can potentially take over the market by displacing its competitors given its primary advantages and higher patient compliance. As the patents of many drugs are expiring in this decade, controlled release drugs have a good opportunity ahead to make a mark in the market.
Contact:
Neeraj Chawla
Kuick Research
Research Head
neeraj@kuickresearch.com
+91-9810410366